Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2008 1
2009 1
2010 1
2011 3
2012 1
2013 4
2014 1
2015 3
2016 4
2017 4
2018 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Immunotherapy for colorectal cancer: where are we heading?
Basile D, Garattini SK, Bonotto M, Ongaro E, Casagrande M, Cattaneo M, Fanotto V, De Carlo E, Loupakis F, Urbano F, Negri FV, Pella N, Russano M, Brunetti O, Scartozzi M, Santini D, Silvestris N, Casadei Gardini A, Puzzoni M, Calvetti L, Cardarelli N, Aprile G. Basile D, et al. Among authors: negri fv. Expert Opin Biol Ther. 2017 Jun;17(6):709-721. doi: 10.1080/14712598.2017.1315405. Epub 2017 Apr 13. Expert Opin Biol Ther. 2017. PMID: 28375039 Free article. Review.
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?
Aprile G, Negri FV, Giuliani F, De Carlo E, Melisi D, Simionato F, Silvestris N, Brunetti O, Leone F, Marino D, Santini D, Dell'Aquila E, Zeppola T, Puzzoni M, Scartozzi M. Aprile G, et al. Among authors: negri fv. Crit Rev Oncol Hematol. 2017 Jul;115:1-12. doi: 10.1016/j.critrevonc.2017.03.025. Epub 2017 Apr 20. Crit Rev Oncol Hematol. 2017. PMID: 28602164 Review.
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?
Giampieri R, Caporale M, Pietrantonio F, De Braud F, Negri FV, Giuliani F, Pusceddu V, Demurtas L, Restivo A, Fontanella C, Aprile G, Cascinu S, Scartozzi M. Giampieri R, et al. Among authors: negri fv. Crit Rev Oncol Hematol. 2016 Apr;100:99-106. doi: 10.1016/j.critrevonc.2016.02.005. Epub 2016 Feb 12. Crit Rev Oncol Hematol. 2016. PMID: 26907512 Review.
Molecular classifications of gastric cancers: Novel insights and possible future applications.
Garattini SK, Basile D, Cattaneo M, Fanotto V, Ongaro E, Bonotto M, Negri FV, Berenato R, Ermacora P, Cardellino GG, Giovannoni M, Pella N, Scartozzi M, Antonuzzo L, Silvestris N, Fasola G, Aprile G. Garattini SK, et al. Among authors: negri fv. World J Gastrointest Oncol. 2017 May 15;9(5):194-208. doi: 10.4251/wjgo.v9.i5.194. World J Gastrointest Oncol. 2017. PMID: 28567184 Free PMC article. Review.
HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.
Fanotto V, Ongaro E, Rihawi K, Avallone A, Silvestris N, Fornaro L, Vasile E, Antonuzzo L, Leone F, Rosati G, Giuliani F, Bordonaro R, Scartozzi M, De Maglio G, Negri FV, Fasola G, Aprile G. Fanotto V, et al. Among authors: negri fv. Oncotarget. 2016 Oct 18;7(42):69060-69074. doi: 10.18632/oncotarget.11264. Oncotarget. 2016. PMID: 27542243 Free PMC article. Review.
FCGR, Cetuximab, and Colorectal Cancer Survival-Letter.
Negri FV, Boggiani D, Rimanti A, Musolino A. Negri FV, et al. Clin Cancer Res. 2016 Oct 1;22(19):4958. doi: 10.1158/1078-0432.CCR-16-1470. Clin Cancer Res. 2016. PMID: 27697992 No abstract available.
Fingerprint Change: Not Visible, But Tangible.
Negri FV, De Giorgi A, Bozzetti C, Squadrilli A, Petronini PG, Leonardi F, Bisogno L, Garofano L. Negri FV, et al. J Forensic Sci. 2017 Sep;62(5):1372-1373. doi: 10.1111/1556-4029.13422. Epub 2017 Jun 12. J Forensic Sci. 2017. PMID: 28605025
PTEN status in advanced colorectal cancer treated with cetuximab.
Negri FV, Bozzetti C, Lagrasta CA, Crafa P, Bonasoni MP, Camisa R, Pedrazzi G, Ardizzoni A. Negri FV, et al. Br J Cancer. 2010 Jan 5;102(1):162-4. doi: 10.1038/sj.bjc.6605471. Epub 2009 Dec 1. Br J Cancer. 2010. PMID: 19953097 Free PMC article.
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib.
Casadei Gardini A, Scarpi E, Faloppi L, Scartozzi M, Silvestris N, Santini D, de Stefano G, Marisi G, Negri FV, Foschi FG, Valgiusti M, Ercolani G, Frassineti GL. Casadei Gardini A, et al. Among authors: negri fv. Oncotarget. 2016 Oct 11;7(41):67142-67149. doi: 10.18632/oncotarget.11565. Oncotarget. 2016. PMID: 27613839 Free PMC article.
22 results